vTv Therapeutics Inc. - VTVT STOCK NEWS

vTv Therapeutics (Nasdaq: VTVT) announced promising results of TTP399, a glucokinase activator for type 1 diabetes (T1D), showing it improves glycemia without increasing hypoglycemia risk. Findings from a JDRF-supported study indicated no cases of diabetic ketoacidosis (DKA) in TTP399-treated participants, while 42% of placebo subjects met DKA criteria. The study, published in Diabetes Obesity and Metabolism and presented at the ADA 2022 conference, supports TTP399's potential as a safe adjunct therapy for T1D.

On June 1, 2022, vTv Therapeutics (Nasdaq: VTVT) announced a $25 million investment from G42 Investments, acquiring 10,386,274 shares at $2.407 each. The investment partly funds Phase 3 clinical trials for TTP399, a glucokinase activator for type 1 diabetes. Additional shares worth $30 million may be issued if the FDA approves TTP399. This collaboration signifies a strategic partnership aimed at accelerating drug development and commercialization, leveraging G42's resources and expertise. TTP399 has shown promising results, including significant reductions in hypoglycemic episodes.

vTv Therapeutics Inc. (Nasdaq: VTVT) reported Q1 2022 financial results, highlighting a revenue of $2 million, primarily due to increased transaction prices from licensing agreements. The company continues to focus on its lead program TTP399 for type 1 diabetes while pausing development on HPP737. As of March 31, 2022, cash reserves were $12.1 million. Net loss before non-controlling interest was $9.4 million, slightly down from $9.5 million in the previous quarter. The diluted net loss per share improved to ($0.10).

vTv Therapeutics Inc. (Nasdaq: VTVT) reported its financial results for Q4 and the full year ended December 31, 2021. The company experienced a net loss of $9.5 million for Q4, increasing from $1.5 million in Q3 2021. Revenue for Q4 was negligible at $9 compared to $3 million in Q3. R&D expenses rose to $5.4 million, while G&A expenses surged to $5.7 million. The company has appointed Richard Nelson as Acting CEO and is focusing on developing TTP399 for type 1 diabetes, with plans for pivotal trials commencing in Q3 2022. Cash decreased to $13.4 million by year-end.

vTv Therapeutics Inc. (Nasdaq: VTVT) announced the appointment of Rich Nelson as Acting CEO following the resignation of Deepa Prasad. Nelson, a board member since 2020, brings extensive experience in corporate development and mergers. Prasad will remain as a Strategic Advisor for six months. The company is focused on advancing its lead drug, TTP399, which received FDA Breakthrough Therapy Designation after showing a 40% reduction in hypoglycemic episodes in its Phase 2 study. vTv aims to launch pivotal trials for TTP399 in 2022.

vTv Therapeutics (Nasdaq: VTVT) has updated its corporate presentation on TTP399, a novel treatment aimed at reducing hypoglycemic episodes in diabetes patients. The drug may act as an oral adjunctive therapy in the $16B insulin market. Nearly 600 patients have been tested with no diabetic ketoacidosis reported. vTv holds worldwide rights for TTP399 and plans global pivotal trials in 2022 while seeking non-dilutive capital through licensing outside North America and Europe. Additionally, the company explores licensing for HPP737 and other assets.

vTv Therapeutics Inc. (Nasdaq: VTVT) announced a 65% workforce reduction to prioritize its lead program, TTP399, for type 1 diabetes, as it prepares for Phase 3 pivotal trials. TTP399 demonstrated a ~40% reduction in hypoglycemic episodes compared to placebo in Phase 2 studies and has received Breakthrough Therapy Designation from the FDA. The company also suspended development on HPP737, a psoriasis treatment, while supporting partnered programs. vTv aims to focus on improving the quality of life for diabetes patients with TTP399.

vTv Therapeutics Inc. (Nasdaq: VTVT) reported third-quarter 2021 financial results, highlighting a cash position of $19.6 million, up from $10.8 million in Q2 2021. The company generated $3.0 million in revenue, largely from milestones achieved with partners. Net loss attributable to shareholders was $1.09 million, or $(0.02) per share, compared to $(0.01) in Q2 2021. The firm is refocusing on TTP399 for type 1 diabetes, having received FDA Breakthrough Therapy Designation. Upcoming pivotal studies for TTP399 are planned for H1 2022, with cost reduction measures being evaluated.

vTv Therapeutics Inc. (Nasdaq: VTVT) announces the appointment of Deepa Prasad as President and CEO, effective immediately, following the retirement of Stephen L. Holcombe. Under her leadership, the company plans to launch phase 3 studies for TTP399, an oral therapy for type 1 diabetes, which received Breakthrough Therapy Designation from the FDA. Recent phase 2 results showed significant HbA1c improvement and reduced hypoglycemia risk. Prasad brings over 20 years of healthcare experience, having previously led investments in prominent firms.